Efficacy observation of epirubicin combined with cyclophosphamide sequential docetaxel neoadjuvant chemotherapy for breast cancer

Liu Zhuixing; Yang Yang; Huang Zhenjia; Hu Shuangshuang; Li Dan; Chen Zhuo; Wang Xinli; Chen Guangwei

doi:10.11986/j.issn.1673-873X.2025.03.06

Abstract：Objective To investigate the efficacy of epirubicin combined with cyclophosphamide sequential docetaxel neoadju-vant chemotherapy for breast cancer,aiming to provide references for clinical treatment.Methods A total of 126 female breast cancer patients admitted to Xi'an International Medical Center Hospital from November 2019 to July 2021 were select-ed as study participants.According to chemotherapy regimens,patients were allocated to a control group(n=62;epirubicin combined with cyclophosphamide and docetaxel)and a study group(n=64;epirubicin combined with cyclophosphamide se-quential docetaxel).After treatment completion,therapeutic efficacy was compared between groups;carbohydrate antigen 153(CA153),tumor-specific growth factor(TSGF)levels,and Quality of Life Questionnaire-Breast Cancer 23(QLQ-BR23)scores before and after treatment were compared.Moreover,toxic and adverse reactions during treatment,1-year and 3-year survival rates after discharge,and surgical completion rates were compared.Results The overall response rates were 68.75%in the study group and 59.68%in the control group,showing no statistically significant difference(P>0.05).Compared with pre-treatment,CA153 and TSGF levels significantly decreased in both groups post-treatment(P<0.05),but intergroup differences were not statistically significant(P>0.05).Before treatment,no differences were noted in body image,breast symptoms,arm symptoms,sexual functioning,or systemic therapy reaction scores between groups(P>0.05).At post-treatment,all of these scores improved compared to pre-treatment in both groups(P<0.05),but no intergroup differences were observed in body image,breast symptoms,arm symptoms,or sexual functioning scores(P>0.05).Systemic therapy reaction scores were significantly lower in the study group than in the control group(P<0.05).Post-treatment incidences of neutropenia,thrombocytopenia,and nausea/vomiting were significantly lower in the study group than in the control group(P<0.05).The 1-year survival rate was significantly higher in the study group than in the control group(P<0.05),while no significant difference was found in the 3-year survival rate(P>0.05).No significant difference was observed in surgical completion rates between groups(P>0.05).Conclusion For neoadjuvant chemothera-py in breast cancer patients,the concurrent regimen(epirubicin in combination with cyclophosphamide and docetaxel)and sequential regimen(epirubicin in combination with cyclophosphamide sequential docetaxel)demonstrate comparable effica-cy.However,sequential administration shows reduced toxicities,improves systemic therapy reaction to a certain extent,and is worthy of clinical promotion.